Evidence map›Paper›PMID 38495157›Full record

ArticleHeliyon2024

Strong YKL-40 expression in the invasive tumor front of colorectal cancer-A pilot study.

Maria Kazakova, Tsvetomira Ivanova, Dorian Dikov, Diana Molander, Kiril Simitchiev, Yordan Sbirkov, Angel M Dzhambov, Victoria Sarafian

Open access · goldAbstract read
In one paragraph

Article in Heliyon, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Maria KazakovaDepartment of Medical Biology, Medical University- Plovdiv, Plovdiv, 4000, Bulgaria.
Tsvetomira IvanovaDepartment of Medical Biology, Medical University- Plovdiv, Plovdiv, 4000, Bulgaria.
Dorian DikovDepartment of General and Clinical Pathology, Grand Hospital de l'Este Francilien, Medical Faculty, Jossigny, 77600, France.
Diana MolanderDepartment of Medical Biology, Medical University- Plovdiv, Plovdiv, 4000, Bulgaria.
Kiril SimitchievDepartment of Analytical Chemistry and Computer Chemistry, Faculty of Chemistry, University of Plovdiv, Plovdiv, 4000, Bulgaria.
Yordan SbirkovDepartment of Medical Biology, Medical University- Plovdiv, Plovdiv, 4000, Bulgaria.
Angel M DzhambovDepartment of Hygiene, Faculty of Public Health, Medical University of Plovdiv, Plovdiv, 4000, Bulgaria.
Victoria SarafianDepartment of Medical Biology, Medical University- Plovdiv, Plovdiv, 4000, Bulgaria.
Medical University Plovdiv · BGInstitut Français · FRPlovdiv University · BG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Тhe poor prognosis of patients initially diagnosed at an advanced stage of colorectal cancer (CRC) and the heterogeneity within the same tumor stage define the need for additional predictive biomarkers. Tumor buds are proposed as a poor prognostic factor for CRC, however, they are still not implemented into routine pathology reporting. In turn, the chitinase-3-like protein 1 (CHI3L1) also known as YKL-40, is regarded as a candidate circulating biomarker and therapeutic target in CRC. The aim of our study was to investigate tissue YKL-40 localization and tumor budding in CRC. Thirty-one CRC patients and normal colonic tissues were examined. The correlation between YKL-40 levels, tumor budding and clinocopathological parameters was evaluated by polychoric correlation analysis. The immunohistochemical assessment revealed high YKL-40 expression in CRC in contrast to normal mucosa. Specifically, intense YKL-40 staining was detected in the front of tumor invasion compared with tumor parenchyma and noncancerous tissue. We present novel data for increased YKL-40 expression in tumor buds within the front of tumor invasion. We assume that the combination of this morphological parameter with the tissue level of the pleotropic YKL-40 glycoprotein could serve as a future prognostic biomarker for CRC stratification and treatment.

Indexed as

Colorectal cancerTumor buddingYKL-40

Identifiers

PMID38495157
PMCPMC10940939
OpenAlexW4392545355

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.